LEARN FROM
every PATIENT.

CancerLinQ Discovery® provides access to a comprehensive deidentified data asset reflecting the longitudinal healthcare experiences of patients with the full range of malignant neoplasms, both solid tumors and heme malignancies. This rich database provides a wealth of insights that enables your business strategy through generating robust real-world evidence.

INDUSTRY LEADING ONCOLOGY
real-world DATABASE

6.5M+	Total patient records	**4.5Y** Average follow-up	**4K+** Providers
21+	Integrated data sources	**50** US states with CancerLinQ patients	**800+** Care sites across 100+ Organizations
15B+	Total database interactions	**67** Median age at diagnosis	**420K+** Records with deep curation
3M+	Patients with cancer	**165K+** Clinical data elements captured	

Disease Description
- Site, histology, grade
- Staging (TNM, other)
- Tissue and circulating biomarkers

Visits
- Clinician
- Infusion

Procedures
- Imaging
- Interventions

Risk Factors
- Family history
- Germline profiling
- Alcohol and tobacco use
- Pain and depression scores
- Comorbidities
- Other health problems and associated medications

Social Determinants of Health

Treatments
- Antineoplastic medications and supportive medications
- Radiation treatment
- Surgery

Outcomes
- Adverse events
- Reasons for treatment discontinuation
- Therapeutic response
- Vital status

Improving clinical outcomes and achieving health equity depend on learning from the experiences of every patient with cancer. CancerLinQ Discovery® sits at the forefront of cancer research, giving you access to richly curated, de-identified patient data drawn from an industry-leading network of participating cancer centers and oncology practices. This powerful database can reveal new knowledge based on unseen trends and patterns in clinical practice—shaping the future of cancer care.

CancerLinQ is proud to offer CancerLinQ Discovery datasets across a growing number of tumor types including the following:

Pan-Cancer	*Prostate*	*Pancreas*
Lung	*Bladder*	*Kidney/Renal Pelvis*
Breast	*Colorectal*	*Muliple Myeloma*
Ovarian	*CLL-SLL*	

RESEARCHERS ARE USING *CancerLinQ Discovery*® DATA TO *accelerate* CANCER RESEARCH.

01 Assess the natural history of both rare and common cancer types across populations.

02 Contribute to post-market safety and label expansion studies.

03 Compare the effectiveness and value of alternative treatment options.

04 Deliver insights to inform and continuously revise practice guidelines and quality measures.

05 Inform health disparities research and surveillance.

06 Provide training datasets for AI model development

07 Provide clinical trial design and feasibility analyses.

08 Study the use of cancer treatments in populations typically excluded from clinical trials due to comorbidities or access challenges, to generate new knowledge to improve care.

BETTER DATA.
BETTER *outcomes.*

CancerLinQ Discovery® includes de-identified patient data from diverse clinical settings, including urban and rural community practices, academic hospitals, and major health systems.

LEARN MORE

CancerLinQ Discovery data is de-identified as to patients and providers. For more information on CancerLinQ Discovery, email *info@cancerlinq.org*.

CancerLinQ Discovery®

WWW.CANCERLINQ.ORG

© 2023 CancerLinQ LLC